Relivyx Plus (lidocaine) NDC 72835-555

NDC codes

FDA NDC Directory

Product NDC (as listed)72835-555Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72835-0555Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72835-555-02	72835055502	1 KIT in 1 CARTON (72835-555-02) * 30 POUCH in 1 PACKAGE (82347-0505-5) / 14 g in 1 POUCH (82347-0505-4) * 89 g in 1 BOTTLE, PLASTIC (72667-073-01)Marketed from Mar 31, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Relivyx Plus
Generic name (nonproprietary): lidocaine
Dosage form: Kit
Labeler: V2 Pharma LLC
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Mar 31, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 72835-555_7485ec1d-074d-4e47-a555-8994173ceb78SPL ID 7485ec1d-074d-4e47-a555-8994173ceb78SPL set ID 08aeb3f5-56ea-4fd7-b151-e6dc65f202daRxCUI 415976, 1745091UPC 0382347050550, 0685757118491

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N472835055502 followed by a unit qualifier and the quantity

Package 72835-0555-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 16, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Lidocaine patch 5% is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)